Kailera Therapeutics, Inc. - Common stock (KLRA)

Could this be what Novo needs to turn things around?

They are fairly risky, but their potential upside is massive.

Don't wait until clinical milestones send their share prices soaring.

Could this be the secret to Pfizer's rebound strategy?

All three could become highly prominent biotech companies within 10 years.

It's important to consider your comfort with risk before diving in.

There's a new challenger to the more established players in the weight-loss drug space.

Kailera Therapeutics, a clinical-stage biotech focused on obesity treatments, just reported a notable insider buy in recent SEC filings.